Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019
About According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.
TechNavio's analysts forecast the Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.
Covered in this Report
The Global CKD Drugs Market can be divided into two segments: Route of Administration which includes oral, SC, and IV and Mechanism of Action which includes ARBs, ACEIs, ESAs, PH Binders, and Vasodilators. This report covers the present scenario and the growth prospects of the Global CKD Drugs market for the period 2014–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CKD that are available in the market.
TechNavio's report, the Global CKD Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global CKD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions
TechNavio Announces the Publication of its Research Report – Global CKD Drugs Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global CKD Drugs Market: Actavis plc, Amgen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd. and Sanofi SA
Other Prominent Vendors in the market are: Abbott Laboratories, Akebia Therapeutics, AMAG Pharmaceuticals, Cara Therapeutics, FibroGen, Keryx Biopharmaceuticals, OPKO Health, Pharmacosmos, Raptor Pharmaceuticals, Reata Pharmaceuticals, Regulus Therapeutics, Rockwell Medical, Shield Therapeutics, Takeda Pharmaceuticals, Vifor Pharma, Xenetic Biosciences and ZS Pharma.
Commenting on the report, an analyst from TechNavio’s team said: “Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market.”
According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years.
Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance.
Actavis, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Sanofi, Abbott Laboratories, Akebia Therapeutic, AMAG Pharmaceuticals, Cara Therapeutics, FibroGen, KeryxBiopharmaceuticals, OPKO Health, Pharmacosmos, Raptor Pharmaceuticals, Reata Pharmaceuticals, Regulus Therapeutics, Rockwell Medical, Shield Therapeutics,Takeda Pharmaceuticals, Vifor Pharma Ltd, Xenetic Biosciences, ZS Pharma